Yuksel Elgin Cansu, Kaner Savci Ilayda, Birisik Yildiz, Hepokur Mustafa
Istanbul University Cerrahpaşa, Istanbul, Turkey.
Int Ophthalmol. 2025 May 10;45(1):188. doi: 10.1007/s10792-025-03556-9.
To assess the macular vascular effects of prolonged use of latanoprost compared to the dorzolamide-timolol fixed combination in patients with very early-stage glaucoma, where glaucoma-specific damage has been minimized.
The retinal vascular effects of latanoprost versus the dorzolamide-timolol fixed combination were evaluated using Optical Coherence Tomography Angiography (OCT-A) in a case-control study design. A total of 71 eyes from 71 individuals were included in the study: 28 eyes receiving latanoprost (Group 1), 20 eyes receiving the dorzolamide-timolol combination (Group 2), and 23 eyes from healthy individuals (Group 3). Superficial, deep, and radial peripapillary capillary plexus vascular density (SCP-vd, DCP-vd, RPCP-vd) and foveal avascular zone (FAZ) measurements were taken with OCT-A. The comparative analysis between groups was performed with SPSS V.26.
Across the groups (from 1 to 3), whole image vascular density (vd) measurements were as follows: SCP-vd: 45.86 ± 3.99, 44.58 ± 4.58, 48.35 ± 4.04; DCP-vd: 44.86 ± 5.75, 44.02 ± 6.87, 49.74 ± 4.84; and RPCP-vd: 46.97 ± 3.81, 47.07 ± 5.49, 49.90 ± 2.43. All these measurements were significantly decreased in both glaucoma groups (groups 1 and 2) compared to healthy subjects (group 3). In subgroup analyses of the macular region, including the fovea, parafovea, and perifovea, vd measurements were decreased in all areas except the fovea in glaucoma patients. However, no statistically significant differences were found between the latanoprost and dorzolamide-timolol groups regarding retinal vascular structure. In FAZ measurements, no significant differences were found in any anatomical location among the three groups.
This study demonstrates that latanoprost, the first prostaglandin analog known for its edema-inducing effect on the macula, does not have a long-term impact on macular vascularity. However, this result should be supported with longer and larger studies.
在青光眼特异性损伤已降至最低的极早期青光眼患者中，评估长期使用拉坦前列素与多佐胺-噻吗洛尔固定复方制剂相比对黄斑血管的影响。
在一项病例对照研究设计中，使用光学相干断层扫描血管造影（OCT-A）评估拉坦前列素与多佐胺-噻吗洛尔固定复方制剂对视网膜血管的影响。该研究共纳入了71名个体的71只眼：28只眼接受拉坦前列素治疗（第1组），20只眼接受多佐胺-噻吗洛尔联合治疗（第2组），以及23只来自健康个体的眼（第3组）。使用OCT-A测量视乳头周围浅表、深层和放射状毛细血管丛的血管密度（SCP-vd、DCP-vd、RPCP-vd）以及黄斑无血管区（FAZ）。使用SPSS V.26对各组之间进行比较分析。
在各组（从第1组到第3组）中，全图像血管密度（vd）测量结果如下：SCP-vd：45.86±3.99、44.58±4.58、48.35±4.04；DCP-vd：44.86±5.75、44.02±6.87、49.74±4.84；RPCP-vd：46.97±3.81、47.07±5.49、49.90±2.43。与健康受试者（第3组）相比，两个青光眼组（第1组和第2组）的所有这些测量值均显著降低。在包括黄斑中心凹、旁黄斑和黄斑周围区域的黄斑区亚组分析中，青光眼患者除黄斑中心凹外所有区域的vd测量值均降低。然而，拉坦前列素组与多佐胺-噻吗洛尔组在视网膜血管结构方面未发现统计学上的显著差异。在FAZ测量中，三组在任何解剖位置均未发现显著差异。
本研究表明，首个因对黄斑有诱导水肿作用而闻名的前列腺素类似物拉坦前列素，对黄斑血管性没有长期影响。然而，这一结果需要更长时间、更大规模的研究予以支持。
